File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD

TitleA randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD
Authors
Issue Date1998
PublisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
Citation
Peritoneal Dialysis International, 1998, v. 18 n. 4, p. 371-375 How to Cite?
AbstractObjective: To compare the therapeutic efficacy of daily oral levofloxacin plus intermittent intraperitoneal (IP) vancomycin (group 1) versus daily IP netromycin and intermittent IP vancomycin (group 2) in the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Design: A randomized multicenter prospective open-label comparative clinical study. Setting: University and Hospital Authority hospitals in Hong Kong. Patients: All CAPD patients who developed bacterial or culture-negative peritonitis beyond 28 days of a previous episode and without evidence of septicemia, associated tunnel infection, or known sensitivity to trial medications were accepted into the clinical trial. Results: A total of 101 patients entered the trial. The primary cure rate was 74.5% for group 1 and 73.6% for group 2. Baseline culture results appeared to influence the clinical outcome: the primary cure rate for culture-negative, gram-positive, and gram-negative episodes was 83.3%, 78.6%, and 42.9% for group 1 and 69.1%, 76.9%, and 71.3% for group 2, respectively. The primary cure rate also varied considerably among individual centers and was particularly noticeable in group 1. In the latter group, it correlated closely with in vitro levofloxacin resistance which in turn correlated closely with previous exposure to fluoroquinolones. Conclusion: Oral levofloxacin in combination with intermittent IP vancomycin has comparable efficacy to IP netromycin combined with intermittent IP vancomycin as primary treatment in CAPD peritonitis, but is simpler and more cost-effective to administer. It may be as primary therapy in centers with relatively low exposure and, therefore, low background resistance to fluoroquinolones.
Persistent Identifierhttp://hdl.handle.net/10722/163345
ISSN
2015 Impact Factor: 1.298
2015 SCImago Journal Rankings: 0.683
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheng, IKPen_US
dc.contributor.authorFang, GXen_US
dc.contributor.authorChau, PYen_US
dc.contributor.authorChan, TMen_US
dc.contributor.authorTong, KLen_US
dc.contributor.authorWong, AKMen_US
dc.contributor.authorLi, CSen_US
dc.contributor.authorLo, WKen_US
dc.contributor.authorCheung, KOen_US
dc.contributor.authorKumana, CRen_US
dc.date.accessioned2012-09-05T05:30:23Z-
dc.date.available2012-09-05T05:30:23Z-
dc.date.issued1998en_US
dc.identifier.citationPeritoneal Dialysis International, 1998, v. 18 n. 4, p. 371-375en_US
dc.identifier.issn0896-8608en_US
dc.identifier.urihttp://hdl.handle.net/10722/163345-
dc.description.abstractObjective: To compare the therapeutic efficacy of daily oral levofloxacin plus intermittent intraperitoneal (IP) vancomycin (group 1) versus daily IP netromycin and intermittent IP vancomycin (group 2) in the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Design: A randomized multicenter prospective open-label comparative clinical study. Setting: University and Hospital Authority hospitals in Hong Kong. Patients: All CAPD patients who developed bacterial or culture-negative peritonitis beyond 28 days of a previous episode and without evidence of septicemia, associated tunnel infection, or known sensitivity to trial medications were accepted into the clinical trial. Results: A total of 101 patients entered the trial. The primary cure rate was 74.5% for group 1 and 73.6% for group 2. Baseline culture results appeared to influence the clinical outcome: the primary cure rate for culture-negative, gram-positive, and gram-negative episodes was 83.3%, 78.6%, and 42.9% for group 1 and 69.1%, 76.9%, and 71.3% for group 2, respectively. The primary cure rate also varied considerably among individual centers and was particularly noticeable in group 1. In the latter group, it correlated closely with in vitro levofloxacin resistance which in turn correlated closely with previous exposure to fluoroquinolones. Conclusion: Oral levofloxacin in combination with intermittent IP vancomycin has comparable efficacy to IP netromycin combined with intermittent IP vancomycin as primary treatment in CAPD peritonitis, but is simpler and more cost-effective to administer. It may be as primary therapy in centers with relatively low exposure and, therefore, low background resistance to fluoroquinolones.en_US
dc.languageengen_US
dc.publisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.comen_US
dc.relation.ispartofPeritoneal Dialysis Internationalen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAnti-Bacterial Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Infective Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshCost-Benefit Analysisen_US
dc.subject.meshDrug Resistance, Microbialen_US
dc.subject.meshFemaleen_US
dc.subject.meshGentamicins - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshGram-Negative Bacterial Infections - Drug Therapyen_US
dc.subject.meshGram-Positive Bacterial Infections - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intraperitonealen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNetilmicin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshOfloxacin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatory - Adverse Effectsen_US
dc.subject.meshPeritonitis - Drug Therapy - Microbiologyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVancomycin - Administration & Dosage - Therapeutic Useen_US
dc.titleA randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPDen_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid10505557-
dc.identifier.scopuseid_2-s2.0-7844231680en_US
dc.identifier.hkuros49827-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-7844231680&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume18en_US
dc.identifier.issue4en_US
dc.identifier.spage371en_US
dc.identifier.epage375en_US
dc.identifier.isiWOS:000076174800004-
dc.publisher.placeCanadaen_US
dc.identifier.scopusauthoridCheng, IKP=7102537483en_US
dc.identifier.scopusauthoridFang, GX=55040637400en_US
dc.identifier.scopusauthoridChau, PY=36509704300en_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US
dc.identifier.scopusauthoridTong, KL=7102473456en_US
dc.identifier.scopusauthoridWong, AKM=7403147057en_US
dc.identifier.scopusauthoridLi, CS=36068236000en_US
dc.identifier.scopusauthoridLo, WK=7201502414en_US
dc.identifier.scopusauthoridCheung, KO=7402406558en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats